Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States

Author:

Loberiza Fausto R.1,Zhang Mei-Jie1,Lee Stephanie J.1,Klein John P.1,LeMaistre Charles F.1,Serna Derek S.1,Eapen Mary1,Bredeson Christopher N.1,Horowitz Mary M.1,Rizzo J. Douglas1

Affiliation:

1. From the University of Nebraska Medical Center, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI; Dana-Farber Cancer Institute, Boston, MA; and Texas Transplant Institute, San Antonio, TX.

Abstract

AbstractThe effect of the organization and delivery of health care at medical centers, referred to as “center effects,” with clinical outcomes after hematopoietic stem cell transplantation (HSCT) is not clear. We examined the association between center and treatment provider factors and mortality after HSCT. We surveyed 163 (87% response rate) United States transplantation centers that performed HLA-identical sibling HSCT for leukemia or autologous HSCT for lymphoma between 1998 and 2000 among patients at least 18 years old. One hundred thirteen (69%) centers performed HLA-identical sibling transplantations, whereas 162 (99%) performed autologous transplantations. Factors associated with decreased 100-day mortality in the allogeneic setting include a higher patient-per-physician ratio (P = .003) and centers where physicians answer calls after office hours (P = .03). Medical school affiliation was not associated with increased 100-day mortality except in centers where students/residents are present without fellows (P = .02). Center effects were weaker in autologous HSCT at 1 year. Differences in 100-day mortality in patients receiving transplants in centers with favorable versus unfavorable factors were greater in allogeneic than autologous HSCT. Greater physician involvement in patient care is important in producing favorable outcomes after HSCT. To more clearly establish the role of the factors we identified, further studies are recommended.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference27 articles.

1. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med. 1992;116: 505-512.

2. Passweg JR, Rowlings PA, Armitage JO, et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry-North America. In: Cecka JM, Teraski PI, ed. Clinical Transplants 1995. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1996: 117-127.

3. Gratwohl A, Hermans J. Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant. 1994;13: 5-10.

4. Appelbaum FR. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J Clin. 1996;46: 142-164.

5. Rowlings PA, Passweg JR, Armitage JO, et al. Current status of allogeneic and autologous blood and marrow transplantation: report from the IBMTR and ABMTR-North America. In: Lanza RP, Chick WL, eds. Yearbook of Cell and Tissue Transplantation. Amsterdam, The Netherlands: Kluwer Academic Publishers; 1996: 19-34.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3